FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma - Cancer Currents Blog National Cancer Institute sent this bulletin at 03/31/2022 10:39 AM EDT The latest from the NCI Cancer Currents blog Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma 03/30/2022 People with advanced multiple myeloma now have another option for CAR T-cell therapy with the recent approval of ciltacabtagene autoleucel (Carvykti). Like the first approved CAR T-cell therapy, Carvykti targets the BCMA protein on myeloma cells.
